GLP-1 receptor agonists are a relatively new class of diabetes medications that imitate a hormone that is missing in type 2 diabetics. According to a recent study published in the journal Diabetes Care, taking a GLP-1 receptor agonist, a class of glucose-lowering medications for type 2 diabetes, may increase the risk of getting thyroid cancer when taken for longer than a year.
Related Post
January 1, 2022
SGLT2 Inhibitors May Help People With Type 2 Diabetes Avoid a Serious COVID-19 Outcome
The likelihood of adverse events, such as admission to
January 1, 2022
Type 1 and Type 2 Diabetes Hospitalizations are Decreased by Continuous Glucose Monitoring
People with type 1 diabetes who utilized a CGM
4 Comments
Comments are closed.
Admin
November 23, 2021 at 8:06 amGrursus mal suada faci lisis Lorem ipsum dolarorit more an ametion dummy consectetur elit Vesti bulum nec odio aea the dumm.
Pluginspoint
November 23, 2021 at 8:09 amGrursus mal suada faci lisis Lorem ipsum dolarorit more a ametion dummy consectetur elit Vesti bulum nec odio aea the dumm.
M. Cox
November 23, 2021 at 8:10 amLorem Ipsum available but the majority is have is suffered alteration in that some form by injected humour or more then randomised.
Tom Cleancy
November 23, 2021 at 8:11 amGrursus mal suada faci lisis Lorem ipsum dolarorit more a ametion dummy consectetur elit Vesti bulum nec odio aea the dumm..